Developing new antiviral treatments for COVID-19
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
This study is working on new medications that can help fight COVID-19 by targeting both the virus and a specific protein in our bodies, with the goal of making treatments more effective for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10693823 on NIH RePORTER |
What this research studies
This research focuses on creating dual inhibitors that target both the viral main protease and a host protein called cathepsin L to combat SARS-CoV-2, the virus responsible for COVID-19. The researchers have identified several promising compounds that show strong antiviral activity in laboratory tests. By using advanced enzymatic assays, they aim to optimize these inhibitors for better effectiveness against the virus. This innovative approach could lead to new antiviral medications that work by disrupting the virus's ability to replicate.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals infected with SARS-CoV-2 or those at high risk of severe COVID-19.
Not a fit: Patients who are not infected with SARS-CoV-2 or who have already recovered from COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective antiviral treatments for COVID-19, potentially reducing the severity and duration of the illness.
How similar studies have performed: Other research has shown promise in developing antiviral agents targeting similar mechanisms, indicating a potential for success with this novel approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Wang, Jun — Rutgers Biomedical and Health Sciences
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.